(E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU)

Medicinal Research Reviews

Volumn 25, Issue 1, 2005, Pages 1-20

  De Clercq, Erik ^a,b,c,d,e  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Stanford University Medical School ^*  (Belgium)

^e Academia Europaea   (Belgium)

Author keywords

(E) 5 (2 bromovinyl) 2 deoxyuridine; (E) 5 (2 bromovinyl)uracil (BVU); Herpes simplex virus type 1 (HSV 1); Varicella zoster virus (VZV)

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5 (2 BROMOVINYL)URACIL; ACICLOVIR; FAMCICLOVIR; FLUOROURACIL; IDOXURIDINE; NETIVUDINE; SORIVUDINE; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; VIDARABINE; VIRUS DNA; ZERPEX; ZOSTEX;

ANTIVIRAL ACTIVITY; BONE MARROW TOXICITY; CLINICAL TRIAL; CYTOSTASIS; DIARRHEA; DRUG DEGRADATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; GENE THERAPY; HERPES LABIALIS; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES ZOSTER; HUMAN; NONHUMAN; PHOSPHORYLATION; REVIEW; SIDE EFFECT; VARICELLA ZOSTER VIRUS;

ANTIVIRAL AGENTS; BROMODEOXYURIDINE; DRUG EVALUATION, PRECLINICAL; HERPESVIRUS 1, HUMAN; HERPESVIRUS 3, HUMAN; PHOSPHORYLATION;

EID: 10344261492     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20011     Document Type: Review

References (116)

1. De Clercq E, Descamps J, Barr PJ, Jones AS, Serafinowski P, Walker RT, Huang GF, Torrence PF, Schmidt CL, Mertes MP, Kulikowski T, Shugar D. Comparative study of the potency and selectivity of anti-herpes compounds. In: Skoda J, Langen P, editors. Antimetabolites in biochemistry, biology, and medicine. Oxford: Pergamon Press; 1979. pp 275-285.
2. Walker RT, Barr PJ, De Clercq E, Descamps J, Jones AS, Serafinowski P. The synthesis and properties of some antiviral nucleosides. Nucleic Acids Res 1978;Special publication no. 4:s103-s106.
3. De Clercq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: A potent and selective anti-herpes agent. Proc Natl Acad Sci USA 1979;76:2947-2951.
4. Bärwolff D, Langen P. A selective bromination of thymidine. Nucleic Acids Res 1975;Special publication no. 1:s29-s31.
5. Reefschläger J, Bärwolff D, Engelmann P, Langen P, Rosenthal HA. Efficiency and selectivity of (E)-5-(2-bromovinyl)-2′-deoxyuridine and some other 5-substituted 2′-deoxypyrimidine nucleosides as antiherpes agents. Antiviral Res 1982;2:41-52.
6. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74:5716-5720.
7. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-Hydroxyethoxymethyl)-guanine activity against viruses of the herpes group. Nature 1978;272:583-585.
8. Lopez C, Watanabe KA, Fox JJ. 2′-Fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother 1980;17:803-806.
9. Watanabe KA, Reichman U, Hirota K, Lopez C, Fox JJ. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′- deoxyarabinofuranosyl-pyrimidine nucleosides. J Med Chem 1979;22: 21-24.
10. De Clercq E. Antiviral agents. In: Greenwood D, O'Grady F, editors. Symposium of the Society for General Microbiology. Scientific Basis of Antimicrobial Chemotherapy. Cambridge: Cambridge University Press; 1985. pp 155-184.
11. De Clercq E. Antiviral and antitumor activities of 5-substituted 2′-deoxyuridines. Meth Find Exp Clin Pharmacol 1980;2:253-267.
12. De Clercq E. Antiviral activity of pyrimidine nucleoside analogs: A structure-function analysis. In: Alderweireldt FC, Esmans EL, editors. Proceedings of the 4th International Round Table on Nucleosides, Nucleotides, and their Biological Applications, Antwerp, 4-6 February 1981. Antwerp: The University of Antwerp; 1982. pp 25-45.
13. De Clercq E. Selective antiherpes agents. Trends Pharmacol Sci 1982;3:492-495.
14. De Clercq E. Antiviral activity of 5-substituted pyrimidine nucleoside analogues. Pure Appl Chem 1983;55:623-636.
15. De Clercq E. The chemotherapy of herpesvirus infections with reference to bromovinyldeoxyuridine and other antiviral compounds. In: Sir Stuart-Harris CH, Oxford J, editors. Problems of antiviral therapy. London: Academic Press; 1983. pp 295-315.
16. De Clercq E. Bromovinyldeoxyuridine (BVDU): Current status in antiviral therapy. In: Kurstak E, editor. Control of virus diseases. New York: Marcel Dekker, Inc.; 1984. pp 443-458.
17. De Clercq E. Therapeutic potentials of bromovinyldeoxyuridine (BVDU) in the treatment of herpesvirus infections. I. Fundamental aspects. In: Rapp F, editor. Herpesvirus. New York: Alan R. Liss, Inc.; 1984. pp 573-585.
18. De Clercq E. Therapeutic potentials of bromovinyldeoxyuridine (BVDU) in the treatment of herpesvirus infections. I. Clinical aspects. In: Rapp F, editor. Herpesvirus. New York: Alan R. Liss, Inc.; 1984. pp 587-599.
19. De Clercq E. Synthetic pyrimidine nucleoside analogues. In: Harnden MR, editor. Approaches to antiviral agents. London: MacMillan Press; 1985. pp 57-99.
20. De Clercq E. Towards a selective chemotherapy of virus infections. Development of bromovinyldeoxyuridine as a highly potent and selective antiherpetic drug. Verh K Acad Geneesk Belg 1986;48:261-290.
21. De Clercq E, Walker RT. Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. Pharmacol Ther 1984;26:1-44.
22. De Clercq E, Walker RT. Chemotherapeutic agents for herpesvirus infections. In: Ellis GP, West GB, editors. Progress in medicinal chemistry, Vol. 23. Amsterdam: Elsevier Science Publishers, B.V.; 1986. pp 187-218.
23. De Clercq E, Verhelst G, Descamps J, Bergstrom DE. Differential inhibition of herpes simplex viruses, type 1 (HSV-1) and type 2 (HSV-2), by (E)-5-(2-X-vinyl)-2′-deoxyuridines. Acta Microbiol Acad Sci Hung 1981;28:307-312.
24. De Clercq E, Desgranges C, Herdewijn P, Sim IS, Walker RT. Bromovinyluracil nucleoside analogues as antiherpes agents. In: Dahlbom R, Nilsson JLG, editors. Proceedings of the VIIIth International Symposium on Medicinal Chemistry, Vol. 1. Stockholm: Swedish Pharmaceutical Press; 1985. pp 198-210.
25. De Clercq E, Descamps J, Verhelst G, Walker RT, Jones AS, Torrence PF, Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis 1980;141:563-574.
26. Shigeta S, Yokota T, Iwabuchi T, Baba M, Konno K, Ogata M, De Clercq E. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis 1983;147:576-584.
27. De Clercq E, Degreef H, Wildiers J, de Jonge G, Drochmans A, Descamps J, De Somer P. Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine in severe herpes zoster. Br Med J 1980;281:1178.
28. Maudgal PC, Missotten L, De Clercq E, Descamps J, De Meuter E. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the topical treatment of herpes simplex keratitis. Albrecht von Graefes Arch Klin Ophthalmol 1981;216:261-268.
29. Wildiers J, De Clercq E. Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine treatment of severe herpes zoster in cancer patients. Eur J Cancer Clin Oncol 1984;20:471-476.
30. Benoit Y, Laureys G, Delbeke M-J, De Clercq E. Oral BVDU treatment of varicella and zoster in children with cancer. Eur J Pediatr 1985;143:198-202.
31. Maudgal PC, De Clercq E. Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents. Curr Eye Res 1991;10(Suppl):193-199.
32. Töpke H, Reefschläger J, Bärwolff D, Halibrand C. Erste Erfahrungen mit dem Antiherpetikum (E)-5-(2-bromvinyl)-2′-desoxyuridin (BrVUdR) bei der Behandlung des Herpes corneae. Folia Ophthal 1984;9: 39-48.
33. Wutzler P, Wutke K, Bärwolff D, Reefschläger J. BVDU-Therapie von Zostererkrankungen bei Patienten mit malignem Grundleiden. Z Gesamte Inn Med 1988;43:677-680.
34. Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003;26:277-289.
35. De Clercq E. The antiviral spectrum of (E)-5-(2-bromovinyl)-2′- deoxyuridine. J Antimicrob Chemother 1984;14(Suppl A):85-95.
36. Neyts J, De Clercq E. In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents. Antimicrob Agents Chemother 1998;42:170-172.
37. Harkness JW, Sands JJ, Sim IS. Bovine herpes mammillitis therapy. Vet Rec 1986:118:282.
38. Smith GA, Whalley JM. (E)-5-(2′-Bromovinyl)-2′-deoxyuridine inhibition of macropodid herpesvirus 1 in vitro. J Zoo Wildlife Med 1998;29:157-159.
39. Smith G. In vitro sensitivity of macropodid herpesvirus 2 to selected anti-herpetic compounds. J Wildlife Dis 1996;32:117-120.
40. Reymen D, Naesens L, Balzarini J, Holý A, Dvoraková H, De Clercq E. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res 1995;28:343-357.
41. Zhang Y, Schols D, De Clercq E. Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Res 1999;43:23-35.
42. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997;41:2754-2756.
43. Andrei G, Snoeck R, Goubau P, Desmyter J, De Clercq E. Comparative activity of various compounds against clinical strains of herpes simplex virus. Eur J Clin Microbiol Infect Dis 1992;11:143-151.
44. Andrei G, Snoeck R, Reymen D, Liesnard C, Goubau P, Desmyter J, De Clercq E. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 1995;14:318-328.
45. Descamps J, De Clercq E. Specific phosphorylation of E-5-(2-iodovinyl)- 2′-deoxyuridine by herpes simplex virus-infected cells. J Biol Chem 1981;256:5973-5976.
46. Allaudeen HS, Kozarich JW, Bertino JR, De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)- 2′-deoxyuridine. Proc Natl Acad Sci USA 1981;78: 2698-2702.
47. Balzarini J, Bernaerts R, Verbruggen A, De Clercq E. Role of the incorporation of (E)-5-(2-iodovinyl)-2′-deoxyuridine and its carbocyclic analogue into DNA of herpes simplex virus type 1-infected cells in the antiviral effects of these compounds. Mol Pharmacol 1990;37:402-407.
48. Mancini WR, De Clercq E, Prusoff WH. The relationship between incorporation of E-5-(2-bromovinyl)-2′-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity. J Biol Chem 1983;258:792-795.
49. Fyfe JA. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′- deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol 1982;21:432-437.
50. Ayisi NK, De Clercq E, Wall RA, Hughes H, Sacks SL. Metabolic fate of (E)-5-(2-bromovinyl)-2′-deoxyuridine in herpes simplex virus- and mock-infected cells. Antimicrob Agents Chemother 1984;26: 762-765.
51. Barr PJ, Oppenheimer NJ, Santi DV. Thymidylate synthetase-catalyzed conversions of E-5-(2-bromovinyl)-2′-deoxyuridylate. J Biol Chem 1983;258:13627-13631.
52. Yokota T, Konno K, Shigeta S. Inhibition of thymidylate synthetase activity induced in varicella-zoster virus infected cells by (E)-5-(2-bromovinyl)-2′-deoxyuridine. Antiviral Chem Chemother 1994;5:191-194.
53. Jennings Wilber BA, Docherty JJ. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2′-deoxyuridine. J Gen Virol 1994;75:1743-1747.
54. Degrève B, Esnouf R, De Clercq E, Balzarini J. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase. Mol Pharmacol 2001;59:285-293.
55. Soike KF, Gibson S, Gerone PJ. Inhibition of simian varicella virus infection of African green monkeys by (E)-5-(2-bromovinyl)-21-deoxyuridine (BVDU). Antiviral Res 1981;1:325-337.
56. Wutzler P, De Clercq E, Wutke K, Färber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double-blind trial. J Med Virol 1995;46: 252-257.
57. Gnann JW, Jr., Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, Borucki MJ, Joseph WP, Mertz GJ, Steigbigel RT, Cloud GA, Soong S-J, Sherrill LC, DeHertogh DA, Whitley RJ, the Collaborative Antiviral Study Group (CASG)/AIDS Clinical Trials Group (ACTG) Herpes Zoster Study Group. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: Results from a randomized, controlled clinical trial. Antimicrob Agents Chemother 1998;42:1139-1145.
58. Wassilew SW, Stubinski BM, Staedtler G, Koch I, Schumacher K, Neubauer A. A randomized, double-blind survey on the effect of brivudin in the prevention of postherpetic pain in comparison with acyclovir. Abstracts of the 4th International Conference on Varicella, Herpes Zoster, and Post-Herpetic Neuralgia, La Jolla, CA, USA, 3-5 March 2001, no. 45.
59. Wassilew SW, Schumacher K, Staedtler G, Koch I, Capriati A, Stubinski BM. Brivudin compared to famciclovir in the prevention of postherpetic neuralgia: A randomized, double-blind multicenter trial. Abstracts of the 4th International Conference on Varicella, Herpes Zoster, and Post-Herpetic Neuralgia, La Jolla, CA, USA, 3-5 March 2001, no. 46.
60. Wassilew SW, Stubinski BM, Koch I, Schumacher K, Städtler G. Brivudin compared to acyclovir and famciclovir: Effect on zoster-associated pain. Abstracts of the 14th International Conference on Antiviral Research, Seattle, WA, USA, 8-13 April 2001. Antiviral Res 2001;50:A90, no. 180.
61. Wassilew SW, Wutzler P, Stubinski BM, Koch I, Staedtler G, Capriati A. Brivudin compared to acyclovir and famciclovir in acute herpes zoster. Abstracts of the CONVIR 2002, European Conference on Viral Diseases, Munich, Germany, 10-12 May 2002. Infection 2002;30(Suppl 1):12, no. 056.
62. Wassilew SW, Wutzler P, Stubinski BM, Koch I, Städtler G, Capriati A. Brivudin compared to acyclovir for the treatment of herpes zoster: Effects on acute disease and postherpetic pain. Abstracts of the 4th European Congress of Chemotherapy and Infection, Paris, France, 5-8 May 2002.
63. Wassilew SW, Stubinski BM, Koch I, Staedtler G, Schumacher K, Capriati A. Oral brivudin for herpes zoster: Results of a famciclovir-controlled study in immunocompetent patients ≥ 50 years. Abstracts of the 10th Annual Meeting of the International Herpes Management Forum (HIMF), 28 February-2 March 2003, no. VZV-03.
64. Wassilew SW, Wutzler P. On behalf of the Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: Results of a randomized, double-blind, multicentered study. Antiviral Res 2003;59:49-56.
65. Wassilew SW, Wutzler P. On behalf of the Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for herpes zoster: A survey study on postherpetic neuralgia. Antiviral Res 2003;59:57-60.
66. Wutzler P, Stubinski BM, Koch I, Staedtler G, Schumacher K. Brivudin compared to acyclovir in the treatment of acute herpes zoster: A randomized, double-blind, multicenter trial. Abstracts of the 4th International Conference on Varicella, Herpes Zoster, and Post-Herpetic Neuralgia, La Jolla, CA, USA, 3-5 March 2001, no. 47.
67. Wutzler P, Wassilew SW, Stubinski BM, Koch I, Schumacher K, Staedtler G. Efficacy and safety of brivudin in the treatment of herpes zoster. Abstracts of the 14th International Conference on Antiviral Research, Seattle, WA, USA, 8-13 April 2001. Antiviral Res 2001, 50:A69, no. 108.
68. Wutzler P, Wassilew SW, Stubinski BM, Koch I, Schumacher K, Städtler G, Capriati A. Efficacy and safety of brivudin in the treatment of herpes zoster. Results of two randomised, controlled clinical trials. Abstracts of the 8th Western Pacific Congress of Chemotherapy and Infectious Diseases, Perth, Australia, 1 -5 December 2002.
69. De Clercq E. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob Agents Chemother 1984;26:155-159.
70. Keizer HJ, DeBruijn EA, Tjaden UR, De Clercq E. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine. J Cancer Res Clin Oncol 1994;120:545-549.
71. Iigo M, Araki E, Nakajima Y, Hoshi A, De Clercq E. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Biochem Pharmacol 1988; 37:1609-1613.
72. Iigo M, Nishikata K-i, Nakajima Y, Hoshi A, De Clercq E. Effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases. Eur J Cancer 1990;26:1089-1092.
73. Okuda H, Nishiyama T, Ogura Y, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi K, Watabe T. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 1997;25:270-273.
74. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998;287:791-799.
75. Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F, Bricaud H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res 1986;46:1094-1101.
76. Ogura K, Nishiyama T, Takubo H, Kato A, Okuda H, Arakawa K, Fukushima M, Nagayama S, Kawaguchi Y Watabe T. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett 1998;122:107-113.
77. Machida H, Watanabe Y, Kano F, Sakata S, Kumagai M, Yamaguchi T. Deglycosylation of antiherpesviral 5-substituted arabinosyluracil derivatives by rat liver extract and enterobacteria cells. Biochem Pharmacol 1995;49:763-766.
78. Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-5-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 1997;7:35-43.
79. Yan J, Tyring SK, McCrary MM, Lee PC, Haworth S, Raymond R, Olsen SJ, Diasio RB. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther 1997;61:563-573.
80. Diasio RB. Sorivudine and 5-fluorouracil: A clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 1998;46:1-4.
81. Kanamitsu S-I, Ito K, Okuda H, Ogura K, Watabe T, Muro K, Sugiyama Y. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil. Drug Metab Dispos 2000;28:467-474.
82. Nishiyama T, Ogura K, Okuda H, Suda K, Kato A, Watabe T. Mechanism-based inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl) uracil in the presence of NADPH. Mol Pharmacol 2000;57:899-905.
83. Balzarini J, De Clercq E, Ayusawa D, Seno T. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxvuridine and related compounds. FEBS Lett 1985;185:95-100.
84. Balzarini J, De Clercq E, Verbruggen A, Ayusawa D, Seno T. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene. Mol Pharmacol 1985;28:581-587.
85. Balzarini J, De Clercq E, Verbruggen A, Ayusawa D, Shimizu K, Seno T. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene. Mol Pharmacol 1987;32:410-416.
86. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2- propoxymethyl)-guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993;268:6332-6337.
87. Balzarini J, Bohman C, Walker RT, De Clercq E. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol Pharmacol 1994;45:1253-1258.
88. Balzarini J, Morin KW, Knaus EE, Wiebe LI, De Clercq E. Novel (E)-5-(2-iodovinyl)-2′-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors. Gene Ther 1995;2:317-322.
89. Degrève B, De Clercq E, Balzarini J. Bystander effect of purine nucleoside analogues in HSV-1tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther 1999;6:162-170.
90. Kim JH, Kim SH, Kolozsvary A, Brown SL, Kim OB, Freytag SO. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 1995;33:861-868.
91. Grignet-Debrus C, Calberg-Bacq CM. Potential of varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells. Gene Ther 1997;4:560-569.
92. Degrève B, Andrei G, Izquierdo M, Piette J, Morin K, Knaus EE, Wiebe LI, Basrah I, Walker RT, De Clercq E, Balzarini J. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. Gene Ther 1997;4:1107-1114.
93. Tomicic MT, Friedrichs C, Christmann M, Wutzler P, Thust R, Kaina B. Apoptosis induced by (E)-5-(2-bromovinyl)-2′-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8. Mol Pharmacol 2003;63:439-449.
94. Mazzacano CA, Fallon AM. Evaluation of a viral thymidine kinase gene for suicide selection in transfected mosquito cells. Insect Mol Biol 1995;4:125-134.
95. Balzarini J, Degrève B, Hatse S, De Clercq E, Breuer M, Johansson M, Huybrechts R, Karlsson A. The multifunctional deoxynucleoside kinase of insect cells is a target for the development of new insecticides. Mol Pharmacol 2000;57:811-819.
96. Weber O. Novel mouse models for the investigation of experimental drugs with activity against human varicella-zoster virus. Antiviral Chem Chemother 2000;11:283-290.
97. Jones AS, Rahim SG, Walker RT, De Clercq E. Synthesis and antiviral properties of (Z)-5-(2-bromovinyl)-2′-deoxyuridine. J Med Chem 1981;24:759-760.
98. Jones AS, Sayers JR, Walker RT, De Clercq E. Synthesis and antiviral properties of (E)-5-(2-bromovinyl)-2′-deoxycytidine-related compounds. J Med Chem 1988;31:268-271.
99. Balzarini J, De Clercq E, Baumgartner H, Bodenteich M, Griengl H. Carbocyclic 5-iodo-2′-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2′-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: Interaction of the (+) and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1. Mol Pharmacol 1990;37:395-401.
100. Spadari S, Ciarrocchi G, Focher F, Verri A, Maga G, Arcamone F, Iafrate E, Manzini S, Garbesi A, Tondelli L. 5-Iodo-2′-deoxy-L-uridine and (E)-5-(2-bromovinyl)-2′-deoxy-L-uridine: Selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity, and cytotoxicity studies. Mol Pharmacol 1995;47:1231-1238.
101. Choi Ys, Li L, Grill S, Gullen E, Lee CS, Gumina G, Tsujii E, Cheng Y-C, Chu CK. Structure-activity relationships of (E)-5-(2-bromovinyl)uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses. J Med Chem 2000;43:2538-2546.
102. Basnak I, Otter GP, Buncombe RJ, Westwood NB, Pietrarelli M, Hardy GW, Mills G, Rahim SG, Walker RT. Efficient syntheses of (E)-5-(2-bromovinyl)- 2′-deoxy-4′-thiouridine. A nucleoside analogue with potent biological activity. Nucleosides Nucleotides 1998;17:29-38.
103. Satoh H, Yoshimura Y, Watanabe M, Ashida N, Ijichi K, Sakata S, Machida H, Matsuda A. Synthesis and antiviral activities of 5-substituted 1-(2-deoxy-2-C-methylene-4-thio-β-D-erythro-pentofuranosyl)uracils. Nucleosides Nucleotides 1998;17:65-79.
104. Kitano K, Machida H, Miura S, Ohrui H. Synthesis of novel 4′-C-methyl-pyrimidirie nucleosides and their biological activities. Bioorg Med Chem Lett 1999;9:827-830.
105. Bamford MJ, Coe PL, Walker RT. Synthesis and antiviral activity of 3′-deoxy-3′-C-hydroxymethyl nucleosides. J Med Chem 1990;33:2494-2501.
106. Ichikawa E, Yamamura S, Kato K. Synthesis of 2′,3′-dideoxy- 3′-C-(hydroxymethyl)-4′-thiopentofuranosyl nucleosides as potential antiviral agent. Bioorg Med Chem Lett 1999;9:1113-1114.
107. Tino JA, Clark JM, Field AK, Jacobs GA, Lis KA, Michalik TL, McGeever-Rubin B, Slusarchyk WA, Spergel SH, Sundeen JE, Tuomari AV, Weaver ER, Young MG, Zahler R. Synthesis and antiviral activity of novel isonucleoside analogs. J Med Chem 1993;36:1221-1229.
108. Soike KF, Huang J-L, Russell JW, Whiterock VJ, Sundeen JE, Stratton LW, Clark JM. Pharmacokinetics and antiviral activity of a novel isonucleoside, BMS-181165, against simian varicella virus infection in African green monkeys. Antiviral Res 1994;23:219-224.
109. Onishi T, Mukai C, Nakagawa R, Sekiyama T, Aoki M, Suzuki K, Nakazawa H, Ono N, Ohmura Y, Iwayama S, Okunishi M, Tsuji T. Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. J Med Chem 2000;43:278-282.
110. Guenther S, Balzarini J, De Clercq E, Nair V. A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity. J Med Chem 2002;45:5426-5429.
111. Russ P, Schelling P, Scapozza L, Folkers G, De Clercq E, Marquez VE. Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine. J Med Chem 2003;46:5045-5054.
112. De Clercq E, Desgranges C, Herdewijn P, Sim IS, Jones AS, McLean MJ, Walker RT. Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine. J Med Chem 1986;29: 213-217.
113. Bernaerts R, Desgranges C, De Clercq E. (E)-5-(2-bromovinyl)uridine requires phosphorylation by the herpes simplex virus (type 1)-induced thymidine kinase to express its antiviral activity. Biochem Pharmacol 1989;38:1955-1961.
114. Farrow SN, Jones AS, Kumar A, Walker RT, Balzarini J, De Clercq E. Synthesis and biological properties of novel phosphotriesters: A new approach to the introduction of biologically active nucleotides into cells. J Med Chem 1990;33:1400-1406.
115. Kumar A, Coe PL, Jones AS, Walker RT, Balzarini J, De Clercq E. Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives. J Med Chem 1990;33:2368-2375.
116. De Clercq E, Walker RT, Whale RF. 3′-O-benzyl-(E)-5-(2-bromovinyl)- 2′-deoxyuridine is active as an anti-herpes agent in vivo but not in vitro. Med Chem Res 1992;2:111-118.